Neos Therapeutics to Host Second Quarter 2018 Financial Results Conference Call on August 8, 2018
August 01 2018 - 7:30AM
Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company
focused on developing, manufacturing and commercializing innovative
extended-release (XR) products using its proprietary
modified-release drug delivery technologies, today announced that
it will report second quarter 2018 financial results prior to the
opening of U.S. financial markets on Wednesday, August 8, 2018.
Neos management will host a conference call and live audio webcast
to discuss these results and provide a company update at 8:30 a.m.
ET that same day.
The live call may be accessed by dialing (877)
388-8985 for domestic calls, or +1 (562) 912-2654 for international
callers, and referencing conference ID number 5853008. A live audio
webcast for the conference call will be available on the Investor
Relations page of the company’s website at
http://investors.neostx.com/.
About Neos TherapeuticsNeos
Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company
focused on developing, manufacturing and commercializing products
utilizing its proprietary modified-release drug delivery technology
platforms. Adzenys XR-ODT® (amphetamine) extended-release orally
disintegrating tablets (see Full Prescribing Information, including
Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release
orally disintegrating tablets (see Full Prescribing Information,
including Boxed WARNING), and Adzenys-ER™ (amphetamine)
extended-release oral suspension (see Full Prescribing Information,
including Boxed WARNING), all for the treatment of ADHD, are the
first three approved products using the Company’s extended-release
technology platform. In addition, Neos manufactures and markets its
generic version of the branded product Tussionex®1, an
extended-release oral suspension of hydrocodone and
chlorpheniramine for the relief of cough and upper respiratory
symptoms of a cold (see Full Prescribing Information, including
Boxed WARNING). Additional information about Neos is available at
www.neostx.com.
1Tussionex® is a registered trademark of the UCB
Group of Companies.
Contacts:
Richard Eisenstadt |
|
Sarah McCabe |
Chief Financial
Officer |
|
Senior Vice
President |
Neos Therapeutics |
|
Stern Investor
Relations, Inc. |
(972) 408-1389 |
|
(212) 362-1200 |
reisenstadt@neostx.com |
|
sarah@sternir.com |
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Sep 2023 to Sep 2024